Ginkgo Bioworks, Inc.

A roundup of the most newsworthy healthcare press releases from PR Newswire, including Eli Lilly's GLP-1 medication study results and business updates from Crunch Fitness and Regulus Therapeutics. NEW YORK, May 9, 2025 /PRNewswire/ -- With thousands of press releases published each month, it can be difficult to keep up with everything on PR Newswire. To help healthcare journalists and consumers stay on top of the month's most popular releases and newsworthy trends, here's a recap of some of the past month's most read- and engaged-with stories. The list below includes the headline (with a link to the full text) and an excerpt from each story. Click on the press release headlines to access accompanying multimedia assets that are available for download. Continue Reading PR Newswire Monthly Health Press Release Roundup, April 2025. Photos provided by Ro, Garmin International, Inc. and Visit Myrtle Beach. Lilly's oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in successful Phase 3 trial "As a convenient once-daily pill, orforglipron may provide a new option and, if approved, could be readily manufactured and launched at scale for use by people around the world," said David A. Ricks, Lilly chair and CEO. The Elizabeth Taylor AIDS Foundation Issues Emergency Grant Cycle to Address Forthcoming Gap Funding Providing financial resources to organizations in need, the initiative will be aimed at ensuring that critical, wrap-around health services for HIV treatment & prevention and programs focused on Transgender communities can continue to operate into the near future. Crunch Fitness Announces Strategic Investment from Leonard Green & Partners Under the terms of the agreement, LGP will acquire a majority interest in Crunch Fitness from TPG Growth, the middle market and growth equity platform of global alternative asset management firm TPG, and Crunch's minority shareholders. Novo Nordisk warns consumers about counterfeit Ozempic® (semaglutide) injection 1 mg in the US Novo Nordisk has become aware of several hundred units of Ozempic® (semaglutide) injection 1 mg distributed outside the Novo Nordisk authorized supply chain in the US. The US Food and Drug Administration (FDA) has also updated its website with information about these counterfeit versions of Ozempic. IMDELLTRA® Demonstrated Superior Overall Survival in Small Cell Lung Cancer IMDELLTRA demonstrated statistically significant and clinically meaningful improvement in overall survival (OS) compared to local standard-of-care (SOC) chemotherapy. Jay Bradner, M.D., executive vice president, Research and Development, at Amgen, commented on the "overwhelming clinical benefit" stating the results "affirm IMDELLTRA as standard of care." Infant Immunization Week: Protecting Our Youngest Against Measles and More As National Infant Immunization Week arrives, Fidelis Care, along with other health experts and The Centers for Disease Control and Prevention (CDC), urge parents to ensure their children receive timely vaccinations, including the measles-mumps-rubella (MMR) vaccine, to safeguard their health and prevent the spread of infectious diseases. Johnson & Johnson MedTech Announces Completion of First Cases with OTTAVA™ Robotic Surgical System OTTAVA is designed as a multi-specialty soft-tissue surgery robot, supporting a broad range of procedures across patient anatomy and surgical specialties, including the most complex surgeries that require a multi-quadrant approach. H.I.G. Capital Completes Acquisition of GetixHealth GetixHealth provides leading revenue cycle management (RCM) solutions to healthcare providers, featuring a comprehensive suite of services that includes patient responsibility management, eligibility and enrollment, third-party claims resolution, patient access, and insurance billing. SHIELD-Utah Study Shows Novavax's COVID-19 Vaccine Induces Lower Reactogenicity Symptoms Compared to mRNA Preliminary data showed Novavax's non-mRNA JN.1 COVID-19 vaccine induced lower frequency and severity of short-term side effects and impact on daily life compared with Pfizer-BioNTech mRNA vaccine. Breakthrough Prize Announces 2025 Laureates in Life Sciences, Fundamental Physics, and Mathematics "This year's Breakthrough Prize laureates have made amazing strides – including treatments for major diseases affecting millions of people worldwide – showing once again the transformative power of curiosity-driven basic science," said Priscilla Chan and Mark Zuckerberg. Ginkgo Bioworks Teams Up with Partners on ARPA-H Project to Stabilize Pharmaceutical Supply Chains - Using Amber Waves of Grain Ginkgo Bioworks and partners were awarded a $29 million contract by ARPA-H to develop distributed manufacturing of essential medicines using wheat germ cell-free expression systems. Kaiser Permanente Debuts Largest Hospital-based Renewable Microgrid in U.S. With 2MW of solar generation and 9MWh of battery storage, the system supports California's clean energy transition, reduces emissions, and saves money while boosting backup generation with renewable power. The Revival of the Ice Bucket Challenge Supports and Highlights the Critical Need for Mental Health Awareness and Discussions: The new viral sensation Takes Over Instagram Quickly Raising Thousands to Benefit the Work of Active Minds More than a decade after the original Ice Bucket Challenge captured global attention in support of the fight against ALS, The University of South Carolina's MIND club (Mental Illness Needs Discussion) has launched a bold, reimagined Ice Bucket Challenge focused on mental health. As part of their campaign, participants are encouraged to donate to Active Minds, the nation's leading nonprofit organization mobilizing youth and young adults to transform mental health norms. Meet vívoactive 6, the latest health and fitness smartwatch from Garmin vívoactive 6 includes Garmin's suite of popular fitness, wellness and smart features, plus an even brighter AMOLED display and up to 11 days of battery life. Regulus Therapeutics Enters into Agreement to be Acquired by Novartis AG Novartis will acquire Regulus for $7.00 per share in cash, with the potential to receive an additional $7.00 per share in cash through a contingent value right, for a total equity value of up to approximately $1.7 billion For more news like this, check out all of the latest health-related releases from PR Newswire. Trending Topics Among the health news that was distributed in April, the PR Newswire team was able to spot several larger stories that highlight the trends shaping the industry. GLP-1 Accessibility: GLP-1 medications maintained their position as healthcare's dominant topic, with April announcements focusing on expanding legitimate access while combating counterfeit products. Novo Nordisk secured two significant victories: successfully blocking unauthorized compounded versions of Wegovy® and Ozempic® while simultaneously expanding patient access through strategic telehealth partnerships. Manufacturing capacity grew with SHL Medical's new $220 million U.S. facility for autoinjectors, while innovation accelerated with Galmed's sublingual semaglutide formulation and Lilly's successful Phase 3 trial results for its oral GLP-1 medication. Consumer-focused initiatives included Ro's partnership with Charles Barkley as a GLP-1 celebrity ambassador and sPiLLRx's launch of an anonymous community platform for medication users, highlighting how companies are anticipating diverse consumer needs while working to maintain medication accessibility. National Autism Awareness Month: April brought significant attention to autism awareness and acceptance, with a notable focus on research findings and innovative support services. New CDC data, shared by The Autism Community in Action, revealed an increase in autism rates, now affecting 1 in 31 U.S. children. Organizations responded with expanded services, such as Goldfish Swim School's new adaptive lesson program and Myrtle Beach's enhanced sensory-friendly initiatives. Healthcare innovations were also prominent, with Acclaim Autism implementing Appian AI technology to reduce patient intake time by 83%, allowing children to receive care months sooner while maintaining HIPAA compliance. National Infant Immunization Week: As measles outbreaks continued to concern health officials, National Infant Immunization Week (April 21-28) generated substantial attention for the importance of childhood vaccinations. HealthTrackRx emerged as a key player, identifying over 10% of nationwide measles cases in their first week of testing. The company also partnered with the CDC to launch a rapid PCR test for H5N1, demonstrating the growing integration between private diagnostic companies and public health infrastructure to address multiple concurrent health threats. Health insurers joined the conversation with Fidelis Care urging parents to maintain vaccination schedules, emphasizing prevention as a cornerstone of pediatric health. Advocacy also expanded globally through Education Cannot Wait's campaign highlighting vaccination as an essential component of international education standards for children in crisis regions. Looking ahead: PR Newswire anticipates significant wire activity in May around Mental Health Awareness Month, National Nurses Week (May 6-12) and Skin Cancer Awareness Month. Early May announcements are expected to recognize National Women's Health Month, likely with maternal health innovations around Mother's Day. Aging and caregiving themes will also likely dominate coverage as organizations prepare for Older Americans Month with activities and resources. Do you have a health press release to distribute? Sign up with PR Newswire to share your story with the audiences who matter most. Helping Journalists Stay Up to Date on Industry News These are just a few of the recent press releases that consumers and the media should know about. To be notified of releases relevant to their coverage area, journalists can set up a custom newsfeed with PR Newswire for Journalists. Once they're signed up, reporters, bloggers, and freelancers have access to the following free features: Customization: Users can create customized newsfeeds that will deliver relevant news right to their inbox. Newsfeed results can be targeted by keywords, industry, subject, geography, and more. Photos and Videos: Thousands of multimedia assets are available to download and include in a journalist or blogger's next story. Subject Matter Experts: Journalists will have access to ProfNet, a database of industry experts to connect with as sources or for quotes in their articles. Related Resources: Our journalist- and blogger-focused blog, Beyond Bylines, features regular media news roundups, writing tips, upcoming events, and more. About PR Newswire PR Newswire is the industry's leading press release distribution partner with an unparalleled global reach of more than 440,000 newsrooms, websites, direct feeds, journalists and influencers and is available in more than 170 countries and 40 languages. From our award-winning Content Services offerings, integrated media newsroom and microsite products, Investor Relations suite of services, paid placement and social sharing tools, PR Newswire has a comprehensive catalog of solutions to solve the modern-day challenges PR and communications teams face. For 70 years, PR Newswire has been the preferred destination for brands to share their most important news stories across the world. For questions, contact the team at [email protected]. SOURCE PR Newswire WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Ginkgo provides an update on its restructuring, including progress towards its expanded $250 million cost savings target Ginkgo and partners awarded $29 million contract by ARPA-H to develop distributed manufacturing of essential medicines using wheat germ cell-free expression systems BOSTON, May 6, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced its results for the first quarter ended March 31, 2025. The update, including a webcast slide presentation with additional details on the first quarter, as well as supplemental financial information will be available at investors.ginkgobioworks.com. First Quarter 2025 Financial Results First quarter 2025 Total revenue of $48 million, up from $38 million in the comparable prior year period, an increase of 27% primarily due to $7 million of non-cash revenue from the release of deferred revenue relating to the mutual termination of a customer agreement. Excluding this impact, Total revenue in the quarter was $41 million, an increase of 8% over the prior year period. Excluding the $7 million non-cash deferred revenue release, first quarter 2025 Cell Engineering revenue of $31 million, up from $28 million in the comparable prior year period, an increase of 10%, primarily driven by growth with biopharma and government customers First quarter 2025 Biosecurity revenue of $10 million, flat to $10 million in the comparable prior year period First quarter 2025 GAAP net loss of $(91) million, compared to $(166) million in the comparable prior year period First quarter 2025 Adjusted EBITDA of $(47) million, up from $(117) million in the comparable prior year period, driven by the increase in revenue as well as a decrease in operating expenses Cash, cash equivalents and marketable securities balance as of March 31, 2025 of $517 million "We're starting the year on a solid base thanks to the significant restructuring efforts of the past year," said Jason Kelly, co-founder and CEO of Ginkgo Bioworks. "Our Solutions business has become a trusted R&D service provider to the US Government and biopharma industry, meanwhile our Tools businesses have traction with existing offerings and are positioned to meet emergent opportunities in areas like AI, which are driving demand for large scale biological datasets. Through all of this, we are maintaining our commitment to achieving our cost reduction targets." Recent Business Highlights & Strategic Positioning Biotechnology remains a critical emerging technology area in the US and Ginkgo is well positioned to provide biosecurity and R&D services Office of Science and Technology Policy (OSTP) Director Michael Kratsios and the National Security Commission on Emerging Biotechnology (NSCEB) report have both recently emphasized biotech as an area of national importance We have 28 US Government projects across Cell Engineering and Biosecurity with ~$180M of contracted backlog and unfunded potential backlog Ginkgo's Datapoints and Automation offerings are seeing new deals and opportunities emerging Datapoints published GDPa1, an antibody developability dataset for 246 IgGs across 10 assays, generated using Ginkgo's high-throughput PROPHET-Ab platform Automation signed a deal recently with Aura Genetics, our first diagnostics company customer We made progress on our objective to reach Adjusted EBITDA breakeven by the end of 2026 Ginkgo's reduction in force and other cost cutting measures have achieved an annualized run-rate cost reduction of $205 million as of the first quarter of 2025, with a target to achieve $250 million in cost reduction by the end of the third quarter of 2025. Site consolidation efforts were substantially completed by the year ended 2024, with excess space available for sublease. Full Year 2025 Guidance Ginkgo previously issued 2025 guidance for Total revenue of $160-$180 million, Cell Engineering revenue of $110-$130 million; and Biosecurity revenue of at least $50 million. Ginkgo updates its previously issued guidance solely to reflect the impact of the previously mentioned $7 million non-cash deferred revenue release in the first quarter to: Total revenue of $167-$187 million in 2025; Cell engineering revenue of $117-$137 million in 2025; and Biosecurity revenue of at least $50 million in 2025. Conference Call Details Ginkgo will host a videoconference today, Tuesday, May 6, 2025, beginning at 5:30 p.m. ET. The presentation will include an overview of the first quarter of 2025, recent business updates, a discussion on Ginkgo's outlook, as well as a moderated question and answer session. To ask a question ahead of the presentation, please submit your questions to @Ginkgo on X (hashtag #GinkgoResults) or by sending an e-mail to [email protected]. A webcast link is available on Ginkgo's Investor Relations website and a replay will be made available following the presentation. Ginkgo Investor Website: Audio-Only Dial Ins: +1 646 931 3860 (New York) +1 301 715 8592 (Washington DC) +1 305 224 1968 (Miami) +1 312 626 6799 (Chicago) +1 346 248 7799 (Houston) +1 408 638 0968 (San Jose) +1 564 217 2000 (Seattle) +1 689 278 1000 (Orlando) Webinar ID: 966 5095 4269 If you experience technical difficulties with any of these dial-ins or if you need international dial-in numbers, please visit our website at for updated dial-in information. About Ginkgo Bioworks Ginkgo Bioworks is the leading horizontal platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Ginkgo Biosecurity is building and deploying the next-generation infrastructure and technologies that global leaders need to predict, detect, and respond to a wide variety of biological threats. For more information, visit ginkgobioworks.com and ginkgobiosecurity.com, read our blog, or follow us on social media channels such as X (@Ginkgo and @Ginkgo_Biosec), Instagram (@GinkgoBioworks), Threads (@GinkgoBioworks) or LinkedIn. Forward-Looking Statements of Ginkgo Bioworks This press release, the presentation, and the conference call and webcast contain certain forward-looking statements within the meaning of the federal securities laws, including statements regarding our plans, strategies, including with respect to our current expectations, operations and anticipated results of operations, both business and financial, including the timing for attaining Adjusted EBITDA breakeven, impacts of our restructuring, potential customer success, including successful application of our offerings by our customers, the regulatory landscape, and expectations with regard to revenue, including our ability to meet all milestones and achieve the maximum revenue available under certain of our customer arrangements, expenses, our full year 2025 outlook, and the market environment, all of which are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements, market trends, or industry results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements generally are identified by the words "believe," "can," "project," "potential," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this document, including but not limited to: (i) our ability to realize near-term and long-term cost savings associated with our site consolidation plans, including the ability to terminate leases or find sub-lease tenants for unused facilities, (ii) volatility in the price of Ginkgo's securities due to a variety of factors, including changes in the competitive and highly regulated industries in which Ginkgo operates and plans to operate, variations in performance across competitors, and changes in laws and regulations affecting Ginkgo's business, (iii) the ability to implement business plans, forecasts, and other expectations, and to identify and realize additional business opportunities, including with respect to our solutions and tools offerings, (iv) the risk of downturns in demand for products using synthetic biology, (v) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (vi) changes to the biosecurity industry, including due to advancements in technology, emerging competition and evolution in industry demands, standards and regulations, (vii) the outcome of any pending or potential legal proceedings against Ginkgo, (viii) our ability to realize the expected benefits from and the success of our Foundry platform programs and Codebase assets, (ix) our ability to successfully develop engineered cells, bioprocesses, data packages or other deliverables, (x) the product development, production or manufacturing success of our customers, (xi) our exposure to the volatility and liquidity risks inherent in holding equity interests in other operating companies and other non-cash consideration we may receive for our services, (xii) the potential negative impact on our business of our restructuring or the failure to realize the anticipated savings associated therewith and (xiii) the uncertainty regarding government budgetary priorities and funding allocated to government agencies. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" section of Ginkgo's annual report on Form 10-K filed with the U.S. Securities and Exchange Commission (the "SEC") on February 25, 2025 and other documents filed by Ginkgo from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Ginkgo assumes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Ginkgo does not give any assurance that it will achieve its expectations. Use of Non-GAAP Financial Measures Certain of the financial measures included in this release, including Adjusted EBITDA, have not been prepared in accordance with generally accepted accounting principles ("GAAP"), and constitute "non-GAAP financial measures" as defined by the SEC. Ginkgo has included these non-GAAP financial measures because it believes they provide an additional tool for investors to use in evaluating Ginkgo's financial performance and prospects. Due to the nature and/or size of the items being excluded, such items do not reflect future gains, losses, expenses or benefits and are not indicative of our future operating performance. These non-GAAP financial measures are supplemental to, and should not be considered in isolation from, or as an alternative to, financial measures determined in accordance with GAAP. In addition, these non-GAAP financial measures may differ from non-GAAP financial measures with comparable names used by other companies. See the reconciliation below for additional information regarding certain of the non-GAAP financial measures included in this release, including a description of these non-GAAP financial measures and a reconciliation of the historic measures to Ginkgo's most comparable GAAP financial measures. Ginkgo Bioworks Contacts: INVESTOR CONTACT: [email protected] MEDIA CONTACT: [email protected] SOURCE Ginkgo Bioworks WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

BOSTON, April 22, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that Ginkgo Automation will design and deploy a Reconfigurable Automation Cart (RAC) system to Aura Genetics, a high-complexity diagnostic laboratory servicing the growing at-home testing and wellness market. This advanced modular laboratory automation platform will be deployed at Aura Genetics' new 22,000-square-foot high-throughput facility at the UPS Healthcare Labport, located at the end of the runway at the Louisville, KY airport. The RAC system, combined with Ginkgo Automation's orchestration software and real-time error resolution services, aims to enable Aura Genetics to efficiently scale and streamline diagnostic testing workflows. Supported by Ginkgo's team of automation engineers and scientists, Aura Genetics expects to be able to process tens of thousands of samples daily, ensuring seamless integration and rapid, high-quality results. "We are proud that Aura Genetics has chosen Ginkgo Automation's RAC system for their new state-of-the-art facility," said Will Serber, General Manager of Ginkgo Automation. "Our modular automation solutions are built to scale with our customers' needs. By deploying this technology, Aura Genetics is setting a new benchmark for efficiency and innovation in laboratory testing, and we look forward to supporting their continued growth." Anthony Nuccio, COO of Aura Genetics, added, "Partnering with Ginkgo Automation marks a significant step forward for Aura Genetics. The sophisticated automation capabilities provided by Ginkgo will allow us to scale our operations efficiently, accelerate turnaround times, and bring innovative lab testing solutions to market more rapidly." The agreement includes extensive collaborative support, including joint protocol development, biovalidation, and dedicated on-demand technical support, reinforcing both companies' commitment to quality, innovation, and scientific rigor. About Ginkgo Bioworks Ginkgo Bioworks is the leading horizontal platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Ginkgo Biosecurity is building and deploying the next-generation infrastructure and technologies that global leaders need to predict, detect, and respond to a wide variety of biological threats. For more information, visit ginkgobioworks.com and ginkgobiosecurity.com, read our blog, or follow us on social media channels such as X (@Ginkgo and @Ginkgo_Biosec), Instagram (@GinkgoBioworks), Threads (@GinkgoBioworks), or LinkedIn. About Aura Genetics Aura Genetics is a pioneering, CLIA Certified and CAP Accredited high-complexity diagnostic laboratory redefining modern diagnostic testing by delivering same-morning results through it's runway-adjacent lab, and joint project with UPS Healthcare. Aura Genetics empowers healthcare providers with actionable 'Lab results at the speed of FLIGHT,' enhancing diagnostics and personalized medicine outcomes. GINKGO BIOWORKS INVESTOR CONTACT: [email protected] GINKGO BIOWORKS MEDIA CONTACT: [email protected] AURA GENETICS MEDIA CONTACT: [email protected] Forward-Looking Statements of Ginkgo Bioworks This press release contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding the capabilities and potential success of the partnership and Ginkgo's cell programming platform. These forward-looking statements generally are identified by the words "believe," "can," "project," "potential," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) our ability to realize near-term and long-term cost savings associated with our site consolidation plans, including the ability to terminate leases or find sub-lease tenants for unused facilities, (ii) volatility in the price of Ginkgo's securities due to a variety of factors, including changes in the competitive and highly regulated industries in which Ginkgo operates and plans to operate, variations in performance across competitors, and changes in laws and regulations affecting Ginkgo's business, (iii) the ability to implement business plans, forecasts, and other expectations, and to identify and realize additional business opportunities, including with respect to our solutions and tools offerings, (iv) the risk of downturns in demand for products using synthetic biology, (v) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (vi) changes to the biosecurity industry, including due to advancements in technology, emerging competition and evolution in industry demands, standards and regulations, (vii) the outcome of any pending or potential legal proceedings against Ginkgo, (viii) our ability to realize the expected benefits from and the success of our Foundry platform programs and Codebase assets, (ix) our ability to successfully develop engineered cells, bioprocesses, data packages or other deliverables, (x) the product development, production or manufacturing success of our customers, (xi) our exposure to the volatility and liquidity risks inherent in holding equity interests in other operating companies and other non-cash consideration we may receive for our services, (xii) the potential negative impact on our business of our restructuring or the failure to realize the anticipated savings associated therewith and (xiii) the uncertainty regarding government budgetary priorities and funding allocated to government agencies. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" section of Ginkgo's annual report on Form 10-K filed with the U.S. Securities and Exchange Commission (the "SEC") on February 25, 2025 and other documents filed by Ginkgo from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Ginkgo assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Ginkgo does not give any assurance that it will achieve its expectations. SOURCE Ginkgo Bioworks WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED